viewBioLargo, Inc.

BioLargo seeks 'to make life better' when it comes to clean water, clean air, and health


Develops innovative products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds, advanced wound care


Quick facts: BioLargo, Inc.

Price: 0.1502 USD

Market: OTCQB
Market Cap: $32.08 m
  • Targets solid waste, wastewater, industrial odor, and advanced wound-care markets
  • Flagship product CupriDyne Clean now marketed to cannabis producers seeking odor elimination
  • Working with US EPA to develop system to remove harmful “forever chemicals” from drinking water

What BioLargo does:

BioLargo Inc (OTCQB:BLGO) is an environmental engineering company with a simple mission “to make life better” when it comes to clean water, clean air, and good health.

The company, based in Westminster, California, has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds (VOC) elimination, and advanced wound care. 

BioLargo operates four subsidiaries: Odor-No-More Inc, BioLargo Water Inc, BioLargo Engineering, Science & Technologies Inc (BLEST), and Clyra Medical Technologies Inc. 

The Odor-No-More division’s main product is CupriDyne Clean Industrial Odor and VOC Eliminator, which is aimed at the solid waste/landfill/compost, wastewater, and oil & gas industries. The product eliminates odor-causing compounds rather than masking them.

The BioLargo Water division develops the Advanced Oxidation System (AOS), an industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than current technologies. 

The BioLargo Engineering division piggybacks on BioLargo Water by offering consulting and engineering services for the water and wastewater treatment industries. It also conducts environmental and Occupational Safety and Health Administration workplace-safety compliance audits.

The engineering division, along with the Odor-No-More unit, is targeting cannabis companies to adopt the company's CupriDyne Clean product, which eliminates the strong, pungent odors and VOCs emitted during growing and production. BioLargo cites some 15,000 cannabis production sites in California as potential customers. 

The Clyra Medical unit develops products and solutions to safely treat chronic wound infections and promote healing while reducing the need for antibiotics. 

Clyra is advancing with its stem-therapy technology called SkinDisc that uses a patient’s own bone marrow and plasma to help heal chronic wounds. The division also has US Food and Drug Administration clearance to market its Clyra Wound Irrigation Solution product for cleansing, irrigating, and debriding dermal wounds and burns.

How is it doing: 

BioLargo’s finances ended 2019 on a high note with hopeful expectations that 2020 will be even better as it ramps up sales and marketing of its flagship products.

Total revenue for 2019 grew by 37% year-over-year to more than $1.8 million, and nearly a third of that was produced in the fourth quarter ended December 31, 2019, thanks to positive cash flow in its Odor-No-More subsidiary. The numbers underscore BioLargo’s strengthening sales momentum heading into 2020. 

The company, which in December was named the “Cleantech Company of the Year” for 2019 by advocacy group Sustain SoCal, also headed into the new decade well capitalized to support its growth strategy.  

It secured a $10 million line of credit, starting with an initial $250,000 investment from Lincoln Park Capital, and retired all but $259,000 of its variable-priced convertible debt. 

BioLargo also recently received a $350,000 infusion from Bookang Tech Co LTD (BKT), a leading wastewater treatment company in South Korea, under an international joint venture (JV) struck in March to manufacture and distribute CupriDyne Clean Industrial Odor and VOC Eliminator products there and in eight other Asian nations in the region. 

In fact, the JV could be lucrative to BioLargo in the long run. The partnership must achieve minimum sales targets to maintain exclusive rights in the Asian markets, and an annual dividend of $2 million will be paid to BioLargo to secure exclusive rights in perpetuity. 

Although the company’s Odor-No-More unit stands as its key revenue driver, BioLargo is further expanding its water and related engineering subsidiaries as demand grows among farmers needing sustainable wastewater filtration systems to governments seeking ways to remove harmful chemicals from the public water supply. 

The water unit’s main product is the Advanced Oxidation System (AOS) that uses highly energized iodine molecules with cutting-edge filtration materials to destroy bacteria and dismantle soluble organic contaminants.

AOS is currently being studied in California to treat stormwater runoff and at the Sunworks Farm in Alberta as part of a commercial trial to manage and treat water and wastewater on the property where organic chicken, turkey, beef and pork products are produced. The trial is a first for BioLargo and the last step before full commercialization of AOS.

In addition, the water subsidiary has launched a pilot program for the treatment of poultry wastewater processing at a facility in Camrose, Alberta and is running another pilot for the treatment of microbrewery wastewater in Joshua Tree, California.

The company has also taken executive steps to advance AOS. It recently hired wastewater industry veteran Tonya Chandler as director of strategic marketing and business development and initiated a regulated crowdfunding operation to secure the necessary funding to launch its water-treatment technology into the $246 million poultry processing market.

Aside from agricultural uses, BioLargo's engineering division sees a huge potential in developing a new water treatment technology to solve a serious global drinking water contamination problem caused by man-made “forever chemicals.”

These chemicals, resistant to breaking down in the environment, are known as per and fluoroalkyl substances, or PFAS. They’ve been inked to cancers, liver damage, low birth weight and other health problems.

BioLargo in 2019 commenced a US Environmental Protection Agency (EPA) sponsored grant to establish proof of a viable treatment system. The company used a device called the Aqueous Electrostatic Concentrator (AEC) that eliminated more than 99% of the two most predominant PFAS compounds. Phase II is planned to see if the AEC is as effective on the rest of the PFAS compounds on the EPA’s target list. 

Meanwhile, the company is doing its part to help support medical providers during the coronavirus (COVID-19) pandemic. BioLargo has started formulating a proprietary product using its core technology in response to a Canadian government request for hand sanitizers.

Inflection points:

  • Secure more environmental-engineering contracts with US Air Force
  • Win FDA pre-market clearance for Clyra wound-healing products
  • Increase sales, especially to licensed cannabis growers, of CurpriDyne Clean product
  • Launch Phase II of EPA grant study of PFAS compounds in water 

What the boss says:

"Our award-winning technologies are validated and marching ahead to commercial adoption," Biolargo CEO Dennis Calvert has said.

"While we are proud of our accomplishments, we are certainly not satisfied because we believe our innovations will continue to grow and find large commercial markets around the world. We have only scratched the surface of our future potential,” he added.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from...


MaxCyte report 'extraordinary first half' with revenue 30% higher than same...

Maxcyte Inc's (LON:MXCT) Doug Doerfler talks to Proactive London about their full-year revenues which are on track to be 'slightly above' current market expectations. Doerfler discusses what he describes as an 'extraordinary first half' with half year revenue 30% higher than the same period...

27 minutes ago

6 min read